Table 2 Univariate (Log-rank test) and multivariate (Cox risk-proportional model) analyses of clinical characteristics and the association between PELI1 and prognosis of PC

Age

<  60

18.53

15.13–21.92

0.223

≥ 60

16.88

14.60–19.17

Gender

Male

19.93

17.15–22.71

0.005

Female

14.29

11.77–16.81

1.601

0.95–2.69

0.007

Tumor size

<  5

20.20

17.87–22.51

0.001

≥ 5

12.31

9.25–15.37

0.833

0.46–1.52

0.55

pTNM stage

I-II

23.01

20.54–25.48

<  0.001

III-IV

10.27

8.62–11.92

2.09

0.97 ~ 4.49

0.06

T stage

I-II

22.12

19.10–25.13

<0.001

III-IV

13.21

11.12–15.30

1.52

0.78 ~ 2.96

0.22

Lymphatic node metastasis

N0

23.56

19.56–22.80

<  0.001

N1

14.53

12.62–16.45

1.07

0.57 ~ 2.00

0.841

Distantly metastasized

M0

20.89

18.60–23.18

<  0.001

M1

9.03

7.23–10.82

3.168

1.64 ~ 6.12

0.001

Number of foci

Single

18.03

15.55–20.50

0.572

Multiple

16.82

13.11–20.54

Vascular invasion

No

19.55

16.63–22.47

0.035

Yes

15.13

12.60–17.65

0.92

0.55 ~ 1.56

0.761

Nerve violation

No

18.44

14.60–22.29

0.508

Yes

17.13

14.88–19.39

Degree of differentiation

Low

16.143

13.23–19.06

0.341

Middle

18.944

15.60–21.89

High

15.214

11.40–19.03

PELI1 IHC Score

1.41

1.27–1.56

<  0.001

1.24

1.08–1.42

0.002

CEA

1.007

0.99–1.01

0.08

CA19–9

1.00

1.00–1.001

0.497